-
1 Comment
Benitec Biopharma Inc is currently in a long term uptrend where the price is trading 1.3% above its 200 day moving average.
From a valuation standpoint, the stock is 82.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 233.0.
Benitec Biopharma Inc's total revenue sank by 100.0% to $1 since the same quarter in the previous year.
Its net income has increased by 100.0% to $-3 since the same quarter in the previous year.
Finally, its free cash flow grew by 99.8% to $-6K since the same quarter in the previous year.
Based on the above factors, Benitec Biopharma Inc gets an overall score of 4/5.
Industry | Biotechnology |
---|---|
Sector | Healthcare |
ISIN | US08205P1003 |
CurrencyCode | USD |
Exchange | NASDAQ |
Target Price | 4 |
---|---|
Market Cap | 6M |
Dividend Yield | 0.0% |
Beta | 1.17 |
PE Ratio | None |
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BNTC using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024